Purigen Biosystems' innovative products offer a truly transformative automated solution for DNA and RNA purification.
Purigen Biosystems' innovative products offer a truly transformative solution for DNA and RNA purification. Their proprietary approach uses isotachophoresis to separate nucleic acids freely in solution without binding or stripping from a physical surface. Because of this, their technology is agnostic to nucleic acid size or sequence and delivers unbiased results ― even from the more challenging sample types like FFPE tissue or low cell counts. Their Ionic Purification System and Kits combine to provide researchers with a fast, efficient, and effective alternative for automated nucleic acid purification.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Apr 2, 2021 | Series Unknown | $34.44M | — | — | — | Detail |
| Jun 12, 2019 | Series B | $26.40M | 4 |
Agilent Technologies
|
— | Detail |
| May 17, 2016 | Series A | $18.20M | 3 |
5AM Ventures
Roche Venture Fund
|
— | Detail |
| Mar 10, 2016 | Series Unknown | $13.01M | — | — | — | Detail |
| Aug 5, 2014 | Debt Financing | $200K | — | — | — | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Agilent Technologies
|
Yes | Series B |
5AM Ventures
|
— | Series B |
Cota Capital
|
— | Series B |
Roche Venture Fund
|
— | Series B |
StartX (Stanford-StartX Fund)
|
— | Series A |